论文部分内容阅读
目的观察玻璃体腔注射康柏西普治疗湿性老年性黄斑变性(AMD)的疗效。方法对经眼底荧光血管造影确诊的湿性AMD患者20例(20眼)给予每个月1次玻璃体腔注射康柏西普0.5mg(0.05ml),连续3次。观察术后1、3、6个月患者最佳矫正视力(BCVA)及黄斑中心凹视网膜厚度(CRT),评估其临床疗效。结果治疗后1、3、6个月,患眼BCVA分别为(47.25±12.34)个字母、(49.87±15.61)个字母、(50.67±14.27)个字母,均较治疗前的(36.10±15.06)个字母提高(P<0.05),治疗后黄斑CRT分别为(294.41±58.17)μm、(287.35±41.53)μm、(275.24±39.49)μm,均较治疗前的(360.51±75.58)μm下降(P<0.05)。随访期间未见严重的不良反应。结论玻璃体腔注射康柏西普治疗湿性AMD可减轻黄斑水肿,提高患者视力。
Objective To observe the curative effect of intravitreal injection of conbercip on wet age-related macular degeneration (AMD). Methods Twenty patients (20 eyes) with wet AMD diagnosed by fundus fluorescein angiography were given intravitreal injection of 0.5 mg (ip) concomitantly 0.5 mg (3 ml) once a month for three consecutive times. The best corrected visual acuity (BCVA) and macular foveal retinal thickness (CRT) were observed at 1, 3 and 6 months after operation to evaluate the clinical effect. Results The BCVA of affected eyes were (47.25 ± 12.34) letters, (49.87 ± 15.61) letters and (50.67 ± 14.27) letters respectively at 1, 3 and 6 months after treatment, which were significantly higher than those before treatment (36.10 ± 15.06) (294.41 ± 58.17) μm, (287.35 ± 41.53) μm and (275.24 ± 39.49) μm, respectively, compared with those before treatment (360.51 ± 75.58 μm, P <0.05) <0.05). No serious adverse reactions were observed during follow-up. Conclusion Intravitreal injection of compstatin in wet AMD can reduce macular edema and improve visual acuity in patients.